Apelin/APJ system: A novel therapeutic target for oxidative stress-related inflammatory diseases (Review)

International Journal of Molecular Medicine

Volumn 37, Issue 5, 2016, Pages 1159-1169

  Zhou, Qun ^a,b   Cao, Jiangang ^a   Chen, Linxi ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apelin; APJ; Atherosclerosis; Hypertension; Inflammation; Ischemia reperfusion injury; Oxidative stress; Reactive oxygen species

Indexed keywords

4 OXO 6 [(PYRIMIDIN 2 YLTHIO)METHYL] 4H PYRAN 3YL 4 NITROBENZOATE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; APELIN; E339 3D6; OPIATE AGONIST; OPIATE ANTAGONIST; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; APLN PROTEIN, HUMAN; APLNR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE;

ARTICLE; ATHEROSCLEROSIS; CARCINOGENESIS; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; MICROANGIOPATHY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN TARGETING; REPERFUSION INJURY; TUMOR GROWTH; ANIMAL; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PREGNANCY; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; CELL TRANSFORMATION, NEOPLASTIC; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; DRUG DISCOVERY; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; REACTIVE OXYGEN SPECIES; RECEPTORS, G-PROTEIN-COUPLED; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84963540175     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2544     Document Type: Article

References (107)

1. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR and Nguyen T: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136: 355-360, 1993.
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, et al: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476, 1998.
3. Xie F, Lv D and Chen L: ELABELA: A novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor. Acta Biochim Biophys Sin (Shanghai) 46: 620-622, 2014.
4. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR and O'Dowd BF: Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74: 34-41, 2000.
5. Saavedra JM, Correa FM, Seltzer A, Pinto JE, Viglione P and Tsutsumi K: Enhanced angiotensin converting enzyme binding in arteries from spontaneously hypertensive rats. J Hypertens 10: 1353-1359, 1992.
6. Choe W, Albright A, Sulcove J, Jaffer S, Hesselgesser J, Lavi E, Crino P and Kolson DL: Functional expression of the seven-transmembrane HIV-1 co-receptor APJ in neural cells. J Neurovirol 6 (Suppl 1): S61-S69, 2000.
7. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, et al: Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1452: 25-35, 1999.
8. Pope GR, Roberts EM, Lolait SJ and O'Carroll AM: Central and peripheral apelin receptor distribution in the mouse: species differences with rat. Peptides 33: 139-148, 2012.
9. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, et al: Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 84: 1162-1172, 2003.
10. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, et al: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279: 26274-26279, 2004.
11. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M and Ruskoaho H: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91: 434-440, 2002.
12. Wang G, Anini Y, Wei W, Qi X, OCarroll AM, Mochizuki T, Wang HQ, Hellmich MR, Englander EW and Greeley GH Jr: Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology 145: 1342-1348, 2004.
13. Castan-Laurell I, Dray C, Attane C, Duparc T, Knauf C and Valet P: Apelin, diabetes, and obesity. Endocrine 40: 1-9, 2011.
14. Lv D, Li L, Lu Q, Li Y, Xie F, Li H, Cao J, Liu M, Wu D, He L and Chen LX: PAK1-coflin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol (In Press).
15. Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J and Fernandez M: Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol 50: 296-305, 2009.
16. Adam F, Khatib AM, Lopez JJ, Vatier C, Turpin S, Muscat A, Soulet F, Aries A, Jardin I, Bobe R, et al: Apelin: an antithrombotic factor that inhibits platelet function. Blood 127: 908-920, 2016.
17. Than A, Zhang X, Leow MK, Poh CL, Chong SK and Chen P: Apelin attenuates oxidative stress in human adipocytes. J Biol Chem 289: 3763-3774, 2014.
18. Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, Parini A and Kunduzova O: Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 584: 2363-2370, 2010.
19. Li L, Li F, Li F, Mao X, Yang L, Huang H, Guo Y, Chen L and Li J: NOX4-derived reactive oxygen species drive apelin-13-induced vascular smooth muscle cell proliferation via the ERK pathway. Int J Pept Res Ther 17: 307-315, 2011.
20. Katugampola SD, Maguire JJ, Matthewson SR and Davenport AP: [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132: 1255-1260, 2001.
21. De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, De Luca B, Laforgia V, Groeger AM and De Luca A: Apelin expression in normal human tissues. In Vivo 16: 333-336, 2002.
22. Kleinz MJ and Davenport AP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118: 119-125, 2004.
23. Li F, Li L, Qin X, Pan W, Feng F, Chen F, Zhu B, Liao D, Tanowitz H, Albanese C and Chen L: Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci 13: 3786-3792, 2008.
24. Liu C, Su T, Li F, Li L, Qin X, Pan W, Feng F, Chen F, Liao D and Chen L: PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim Biophys Sin (Shanghai) 42: 396-402, 2010.
25. Mao XH, Tao S, Zhang XHui, Li F, Qin XP, Liao DF, Li LF and Chen LX: Apelin-13 promotes monocyte adhesion to human umbilical vein endothelial cell mediated by phosphatidylinositol 3-kinase signaling pathway. Prog Biochem Biophys 38: 1162-1170, 2011.
26. Lu Y, Zhu X, Liang GX, Cui RR, Liu Y, Wu SS, Liang QH, Liu GY, Jiang Y, Liao XB, et al: Apelin-APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-κB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids 43: 2125-2136, 2012.
27. Lassègue B and Clempus RE: Vascular NAD(P)H oxidases: Specifc features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277-R297, 2003.
28. Potdar S and Kavdia M: NO/peroxynitrite dynamics of high glucose-exposed HUVECs: Chemiluminescent measurement and computational model. Microvasc Res 78: 191-198, 2009.
29. Cohen RA and Tong X: Vascular oxidative stress: The common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol 55: 308-316, 2010.
30. Liang JH, Li YN, Qi JS and Jia XX: Peroxynitrite-induced protein nitration is responsible for renal mitochondrial damage in diabetic rat. J Endocrinol Invest 33: 140-146, 2010.
31. Li L, Li L, Xie F, Zhang Z, Guo Y, Tang G, Lv D, Lu Q, Chen L and Li J: Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin (Shanghai) 45: 875-881, 2013.
32. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, Ishida J, Toya Y, Kiuchi Y, Hirawa N, et al: Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 171: 1705-1712, 2007.
33. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, Tsao PS, Dalman RL and Quertermous T: Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 296: H1329-H1335, 2009.
34. Lv D, Li H and Chen L: Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 45: 527-533, 2013.
35. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR and O'Dowd BF: Modifcation of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 146: 231-236, 2005.
36. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K and Fujimiya M: The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99: 87-92, 2001.
37. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD and Newby DE: Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure. Circulation 121: 1818-1827, 2010.
38. Dikalova AE, Góngora MC, Harrison DG, Lambeth JD, Dikalov S and Griendling KK: Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol 299: H673-H679, 2010.
39. Ghiadoni L, Taddei S and Virdis A: Hypertension and endothelial dysfunction: Therapeutic approach. Curr Vasc Pharmacol 10: 42-60, 2012.
40. Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE and Smith LH: Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 29: 724-731, 2011.
41. Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama K, Nishimura S, Inagami T and Senbonmatsu T: Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res 34: 701-706, 2011.
42. Ryu S, Ornoy A, Samuni A, Zangen S and Kohen R: Oxidative stress in Cohen diabetic rat model by high-sucrose, low-copper diet: Inducing pancreatic damage and diabetes. Metabolism 57: 1253-1261, 2008.
43. Kitada M, Kume S, Imaizumi N and Koya D: Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643, 2011.
44. Lee SH, Nam BY, Kang EW, Han SH, Li JJ, Kim H, Kim SH, Kwak SJ, Park JT, Chang TI, et al: Effects of an oral adsorbent on oxidative stress and fbronectin expression in experimental diabetic nephropathy. Nephrol Dial Transplant 25: 2134-2141, 2010.
45. Ha H, Yu MR, Choi YJ, Kitamura M and Lee HB: Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13: 894-902, 2002.
46. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M and Ito S: Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 17: 11-15, 2003.
47. Day RT, Cavaglieri RC and Feliers D: Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol 304: F788-F800, 2013.
48. Nishida M, Okumura Y, Oka T, Toiyama K, Ozawa S, Itoi T and Hamaoka K: The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fbrosis. Nephron Extra 2: 39-47, 2012.
49. Cameron NE and Cotter MA: Pro-infammatory mechanisms in diabetic neuropathy: Focus on the nuclear factor kappa B pathway. Curr Drug Targets 9: 60-67, 2008.
50. Ganesh Yerra V, Negi G, Sharma SS and Kumar A: Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy. Redox Biol 1: 394-397, 2013.
51. Zeng XJ, Yu SP, Zhang L and Wei L: Neuroprotective effect of the endogenous neural peptide apelin in cultured mouse cortical neurons. Exp Cell Res 316: 1773-1783, 2010.
52. Simó R, Carrasco E, García-Ramírez M and Hernández C: Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98, 2006.
53. Tao Y, Lu Q, Jiang YR, Qian J, Wang JY, Gao L and Jonas JB: Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 51: 4237-4242, 2010.
54. Lu Q, Feng J and Jiang YR: The role of apelin in the retina of diabetic rats. PLoS One 8: e69703, 2013.
55. Saint-Geniez M, Masri B, Malecaze F, Knibiehler B and Audigier Y: Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev 110: 183-186, 2002.
56. Cain K, Bratton SB and Cohen GM: The Apaf-1 apoptosome: A large caspase-activating complex. Biochimie 84: 203-214, 2002.
57. Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y, Yamamoto K, Higaki J, Yasufumi K and Ogihara T: Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: In vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 86: 974-981, 2000.
58. Di Stilo A, Chegaev K, Lazzarato L, Fruttero R, Gasco A, Rastaldo R and Cappello S: Effects of nitric oxide donor antiox-idants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury. Arzneimittelforschung 59: 111-116, 2009.
59. Rastaldo R, Cappello S, Folino A, Di Stilo A, Chegaev K, Tritto I, Pagliaro P and Losano G: Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts. J Physiol Pharmacol 61: 21-27, 2010.
60. Chen Z, Li T and Zhang B: Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res 145: 287-294, 2008.
61. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ and Tang CS: Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30: 1144-1152, 2009.
62. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM and Smith CC: Apelin-13 and apelin-36 exhibit direct cardiopro-tective activity against ischemia-reperfusion injury. Basic Res Cardiol 102: 518-528, 2007.
63. Sorli SC, Le Gonidec S, Knibiehler B and Audigier Y: Apelin is a potent activator of tumour neoangiogenesis. Oncogene 26: 7692-7699, 2007.
64. Han S, Wang G, Qi X, Lee HM, Englander EW and Greeley GH Jr: A possible role for hypoxia-induced apelin expression in enteric cell proliferation. Am J Physiol Regul Integr Comp Physiol 294: R1832-R1839, 2008.
65. Liu J and Wang Z: Increased oxidative stress as a selective anti-cancer therapy. Oxid Med Cell Longev 2015: 294303, 2015.
66. Sawicka E, Lisowska A, Kowal P and Długosz A: The role of oxidative stress in bladder cancer. Postepy Hig Med Dosw (Online) 69: 744-752, 2015 (In Polish).
67. Raina K, Tyagi A, Kumar D, Agarwal R and Agarwal C: Role of oxidative stress in cytotoxicity of grape seed extract in human bladder cancer cells. Food Chem Toxicol 61: 187-195. 2013.
68. Tong L, Chuang CC, Wu S and Zuo L: Reactive oxygen species in redox cancer therapy. Cancer Lett 367: 18-25, 2015.
69. Shipitsin M and Polyak K: The cancer stem cell hypothesis: In search of definitions, markers, and relevance. Lab Invest 88: 459-463, 2008.
70. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
71. Shi X, Zhang Y, Zheng J and Pan J: Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16: 1215-1228, 2012.
72. Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, Qian X, Yu J, Li Y, Xu X, et al: Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 63: 535-540, 2013.
73. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA and Barata JT: PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest: 3762-3774, 2008.
74. Min KJ, Lee JT, Joe EH and Kwon TK: An IκBα phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-κB-independent mechanism. Cell Signal 23: 1505-1513, 2011.
75. Khaksari M, Aboutaleb N, Nasirinezhad F, Vakili A and Madjd Z: Apelin-13 protects the brain against ischemic reper-fusion injury and cerebral edema in a transient model of focal cerebral ischemia. J Mol Neurosci 48: 201-208, 2012.
76. Bao HJ, Zhang L, Han WC and Dai DK: Apelin-13 attenuates traumatic brain injury-induced damage by suppressing autophagy. Neurochem Res 40: 89-97, 2015.
77. Kasai A, Kinjo T, Ishihara R, Sakai I, Ishimaru Y, Yoshioka Y, Yamamuro A, Ishige K, Ito Y and Maeda S: Apelin defciency accelerates the progression of amyotrophic lateral sclerosis. PLoS One 6: e23968, 2011.
78. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R and Takakura N: Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27: 522-534, 2008.
79. Inuzuka H, Nishizawa H, Inagaki A, Suzuki M, Ota S, Miyamura H, Miyazaki J, Sekiya T, Kurahashi H and Udagawa Y: Decreased expression of apelin in placentas from severe pre-eclampsia patients. Hypertens Pregnancy 32: 410-421, 2013.
80. Bortoff KD, Qiu C, Runyon S, Williams MA and Maitra R: Decreased mater nal plasma apelin concentrations in preeclampsia. Hypertens Pregnancy 31: 398-404, 2012.
81. Furuya M, Okuda M, Usui H, Takenouchi T, Kami D, Nozawa A, Shozu M, Umezawa A, Takahashi T and Aoki I: Expression of angiotensin II receptor-like 1 in the placentas of pregnancy-induced hypertension. Int J Gynecol Pathol 31: 227-235, 2012.
82. Vatish M, Randeva HS and Grammatopoulos DK: Hormonal regulation of placental nitric oxide and pathogenesis of pre-eclampsia. Trends Mol Med 12: 223-233, 2006.
83. Han S, Wang G, Qi X, Englander EW and Greeley GH Jr: Involvement of a Stat3 binding site in infammation-induced enteric apelin expression. Am J Physiol Gastrointest Liver Physiol 295: G1068-G1078, 2008.
84. 2 in IPEC-J2 cells. Mol Cell Biochem 378: 73-81, 2013.
85. Baregamian N, Song J, Jeschke MG, Evers BM and Chung DH: IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis. J Surg Res 136: 31-37, 2006.
86. Gad GI, Ismail RI, El-Masry SA and Gouda HR: Serum apelin in early-onset neonatal sepsis: Is it diagnostic? J Neonatal Perinatal Med 7: 207-212, 2014.
87. Lesur O, Roussy JF, Chagnon F, Gallo-Payet N, Dumaine R, Sarret P, Chraibi A, Chouinard L and Hogue B: Proven infection-related sepsis induces a differential stress response early after ICU admission. Crit Care 14: R131, 2010.
88. Pan CS, Teng X, Zhang J, Cai Y, Zhao J, Wu W, Wang X, Tang CS and Qi YF: Apelin antagonizes myocardial impairment in sepsis. J Card Fail 16: 609-617, 2010.
89. Mertens K, Lowes DA, Webster NR, Talib J, Hall L, Davies MJ, Beattie JH and Galley HF: Low zinc and selenium concentrations in sepsis are associated with oxidative damage and infammation. Br J Anaesth 114: 990-999, 2015.
90. Bar-Or D, Carrick MM, Mains CW, Rael LT, Slone D and Brody EN: Sepsis, oxidative stress, and hypoxia: Are there clues to better treatment? Redox Rep 20: 193-197, 2015.
91. Rastaldo R, Cappello S, Folino A and Losano G: Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antioxid Redox Signal 14: 909-922, 2011.
92. Azizi Y, Faghihi M, Imani A, Roghani M and Nazari A: Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 46: 76-82, 2013.
93. Chen XY, Liu XM, Feng LL and Tang CS: Changes and clinical signifcance of serum Apelin in patients with severe sepsis and septic shock. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30: 131-135, 2008 (In Chinese).
94. Cao J, Li H and Chen L: Targeting drugs to APJ receptor: The prospect of treatment of hypertension and other cardiovascular diseases. Curr Drug Targets 16: 148-155, 2015.
95. Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, et al: Identifcation and pharmacological properties of E339-3D6, the frst nonpeptidic apelin receptor agonist. FASEB J 24: 1506-1517, 2010.
96. Khan P, Maloney PR, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, et al: Functional Agonists of the Apelin (APJ) Receptor. Probe Reports from the NIH Molecular Libraries Program [Internet]. Last Update: Dec 12, 2011.
97. Mendez M: Renin release: Role of SNAREs. Am J Physiol Regul Integr Comp Physiol 307: R484-R486, 2014.
98. Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, et al: Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitro-benzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett 22: 6656-6660, 2012.
99. Zhou N, Fang J, Acheampong E, Mukhtar M and Pomerantz RJ: Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology 312: 196-203, 2003.
100. Zhang Y, Maitra R, Harris DL, Dhungana S, Snyder R and Runyon SP: Identifying structural determinants of potency for analogs of apelin-13: Integration of C-terminal truncation with structure-activity. Bioorg Med Chem 22: 2992-2997, 2014.
101. Jin G, Yang P, Gong Y, Fan X, Tang J and Lin J: Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats. Zhongguo Zhong Yao Za Zhi 34: 3263-3267, 2009 (In Chinese).
102. Wu D, He L and Chen L: Apelin/APJ system: A promising therapy target for hypertension. Mol Biol Rep 41: 6691-6703, 2014.
103. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D and Llorens-Cortes C: Functional dissociation of apelin receptor signaling and endocytosis: Implications for the effects of apelin on arterial blood pressure. J Neurochem 90: 1290-1301, 2004.
104. Zhang BH, Wang W, Wang H, Yin J and Zeng XJ: Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One 8: e60457, 2013.
105. Chen H, Wan D, Wang L, Peng A, Xiao H, Petersen RB, Liu C, Zheng L and Huang K: Apelin protects against acute renal injury by inhibiting TGF-β1. Biochim Biophys Acta 1852: 1278-1287, 2015.
106. Yang Y, Zhang X, Cui H, Zhang C, Zhu C and Li L: Apelin-13 protects the brain against ischemia/reperfusion injury through activating PI3K/Akt and ERK1/2 signaling pathways. Neurosci Lett 568: 44-49, 2014.
107. Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J and Bai B: Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of infammation. Peptides 63: 55-62, 2015.